metricas
covid
Medicina Clínica (English Edition) Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admis...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
Valor del aumento del biomarcador supresor soluble de tumorigenicidad 2 (sST2) al ingreso como indicador de gravedad en pacientes con COVID-19
María Arnaldos-Carrilloa,b, José Antonio Noguera-Velascoa,b,c, Isabel M. Martínez-Ardilg, Alejandro Riquelme-Pérezb,f, Iria Cebreiros-Lópeza,b,c, Álvaro Hernández-Vicenteb, José Antonio Ros-Lucash,i, Amjad Khank, Antoni Bayes-Genísf,j, Domingo Pascual-Figalb,c,d,e,f,
Corresponding author
dpascual@um.es

Corresponding author.
a Clinical Laboratory Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
b Universidad de Murcia, Murcia, Spain
c IMIB Pascual Parrilla, Murcia, Spain
d Cardiology Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
e Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
f CIBER Cardiovascular, Madrid, Spain
g Family and Community Medicine, Servicio Murciano de Salud, Murcia, Spain
h Pneumology Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
i Universidad Católica de Murcia (UCAM), Murcia, Spain
j Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
k Nuffield Division of Clinical Laboratory Sciences (NDCLS), Radcliffe Department of Medicine, John Radcliffe hospital, University of Oxford, Oxford, UK
Ver más
Read
257
Times
was read the article
0
Total PDF
257
Total HTML
Share statistics
Article information
ISSN: 23870206
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 10 13 0 13
2025 9 12 0 12
2025 8 11 0 11
2025 7 24 0 24
2025 6 13 0 13
2025 5 19 0 19
2025 4 21 0 21
2025 3 17 0 17
2025 2 14 0 14
2025 1 17 0 17
2024 12 6 0 6
2024 11 6 0 6
2024 10 5 0 5
2024 9 25 0 25
2024 8 21 0 21
2024 7 11 0 11
2024 6 5 0 5
2024 5 2 0 2
2024 4 2 0 2
2024 3 7 0 7
2024 1 5 0 5
2023 12 1 0 1
Show all

Follow this link to access the full text of the article